Breaking News Instant updates and real-time market news.

AXON

Axovant Sciences

$13.52

0.07 (0.52%)

12:31
11/23/16
11/23
12:31
11/23/16
12:31

Axovant Sciences outlook unchanged on Lilly's solanezumab failure, says Baird

  • 29

    Nov

AXON Axovant Sciences
$13.52

0.07 (0.52%)

09/23/16
PIPR
09/23/16
NO CHANGE
Target $32
PIPR
Overweight
Axovant Sciences selloff provides entry point, says Piper Jaffray
Piper Jaffray analyst Charles Duncan believes yesterday's selloff in shares of Axovant Sciences provides an entry point into the name. Lundbeck's announcement that its first Phase III data with idalopirdine in Alzheimer's missed the primary endpoint does not have predictive value for the Axovant's ongoing RVT-101 Phase III study, Duncan tells investors in a research note. The analyst sees "several key differences" between the two candidates and Phase III programs. He believes RVT-101 is the best-in-class 5-HT6 candidate and thinks its MINDSET trial is well designed to show clinical benefit. Duncan reiterates an Overweight rating on Axovant with a $32 price target.
09/22/16
HCWC
09/22/16
NO CHANGE
Target $35
HCWC
Buy
No read-through from idalopirdine to Axovant RVT-101, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein notes that Lundbeck announced that its idalopirdine missed its primary and secondary endpoints in the STARSHINE Phase 3 study in mild/moderate Alzheimer's disease. However, Fein says that idalopirdine miss does not shake his confidence in Axovant's RVT-101 as he believes Lundbeck may have simply not been able to dose idalopirdine high enough in the Phase 3 program, which minimizes read-through to Axovant's MINDSET Phase 3 study. He continues to believe that Axovant's own experimental Alzheimer's therapy is well positioned for a win. Fein reiterates a Buy rating and $35 price target on Axovant's shares. In afternoon trading, Axovant's stock has dropped almost 12% to $15.31 per share.
09/22/16
CHDN
09/22/16
NO CHANGE
Target $8
CHDN
Sell
Recent failures of 5-HT6 competitors reinforce Axovant risks, says Chardan
After Lundbeck reported that its 5-HT6 antagonist, idalopirdine, did not meet the primary endpoint in the first of three phase III studies in mild-to-moderate Alzheimer's disease patients, Chardan analyst Gbola Amusa noted that this is the second recent failure of a mid-to-late-stage 5-HT6 antagonist coming on the heels of Pfizer's (PFE) prior miss. Amusa anticipates that some in the market will see limited read-across from Lundbeck to Axovant (AXON), but he thinks Pfizer's and Lundbeck's setbacks reinforce the risks for the 5-HT6 antagonist class in Alzheimer's. The analyst reiterates his Sell rating and $8 price target on Axovant shares.
09/22/16
JMPS
09/22/16
NO CHANGE
JMPS
Axovant Sciences weakness an opportunity, says JMP Securities

TODAY'S FREE FLY STORIES

ALNY

Alnylam

$42.25

1.445 (3.54%)

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Hot Stocks
Breaking Hot Stocks news story on Alnylam »

Dodge & Cox reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

$NYE

NYSE Market Internals

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVO

Cenveo

$6.84

-0.16 (-2.29%)

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Hot Stocks
Breaking Hot Stocks news story on Cenveo »

Brigade Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:16
12/09/16
12/09
16:16
12/09/16
16:16
Technical Analysis
NASDAQ market internals summary »

Volume is very heavy for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$1.33

-0.04 (-2.92%)

16:15
12/09/16
12/09
16:15
12/09/16
16:15
Hot Stocks
Cellectar, INC Research enter into Work Order »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$14.40

0.86 (6.35%)

16:12
12/09/16
12/09
16:12
12/09/16
16:12
Hot Stocks
Breaking Hot Stocks news story on International Seaways »

Cyrus Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFS

Saul Centers

$66.45

-0.96 (-1.42%)

16:09
12/09/16
12/09
16:09
12/09/16
16:09
Hot Stocks
Saul Centers raises quarterly dividend 8.5% to 51c from 47c per share »

The dividend is to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASNA

Ascena Retail

$8.04

-0.07 (-0.86%)

16:08
12/09/16
12/09
16:08
12/09/16
16:08
Hot Stocks
Ascena Retail names David Jaffe chairman of the board »

Ascena Retail announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MORN

Morningstar

16:08
12/09/16
12/09
16:08
12/09/16
16:08
Hot Stocks
Morningstar raises quarterly dividend to 23c from 22c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAND

Sandstorm Gold

$3.83

-0.19 (-4.73%)

16:07
12/09/16
12/09
16:07
12/09/16
16:07
Syndicate
Breaking Syndicate news story on Sandstorm Gold »

Sandstorm Gold files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIU

AC Immune

$14.93

2.88 (23.90%)

, RHHBY

Roche

$27.86

0.78 (2.88%)

16:05
12/09/16
12/09
16:05
12/09/16
16:05
Hot Stocks
AC Immune partner Genentech presents 'important' data on Alzheimer's therapy »

AC Immune (ACIU)…

ACIU

AC Immune

$14.93

2.88 (23.90%)

RHHBY

Roche

$27.86

0.78 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDVX

Medovex

$1.50

0.03 (2.04%)

16:03
12/09/16
12/09
16:03
12/09/16
16:03
Hot Stocks
Breaking Hot Stocks news story on Medovex »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$78.79

-1.69 (-2.10%)

16:01
12/09/16
12/09
16:01
12/09/16
16:01
Hot Stocks
Belden extends shareholder rights agreement »

Belden announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GENE

Genetic Technologies

$1.19

-0.01 (-0.83%)

15:59
12/09/16
12/09
15:59
12/09/16
15:59
Hot Stocks
Breaking Hot Stocks news story on Genetic Technologies »

CVI Investments reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLO

Flowers Foods

$19.26

2.2325 (13.11%)

15:53
12/09/16
12/09
15:53
12/09/16
15:53
Recommendations
Flowers Foods analyst commentary  »

Flowers Foods settlement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$54.22

-0.21 (-0.39%)

15:50
12/09/16
12/09
15:50
12/09/16
15:50
Options
Halliburton Dec 48.5 puts for a nickel per contract »

Halliburton Dec 48.5 puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BIIB

Biogen

$289.54

4.24 (1.49%)

15:43
12/09/16
12/09
15:43
12/09/16
15:43
Recommendations
Biogen analyst commentary  »

Piper says Biogen still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLO

Valero

$67.84

-0.535 (-0.78%)

15:40
12/09/16
12/09
15:40
12/09/16
15:40
Options
Higher option volume in Valero driven by downside put purchases »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKLN

Skyline Medical

$2.94

-0.01 (-0.34%)

15:36
12/09/16
12/09
15:36
12/09/16
15:36
Syndicate
Skyline Medical files to sell 1.925M units »

Each unit consisting of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$4.26

-0.08 (-1.84%)

15:35
12/09/16
12/09
15:35
12/09/16
15:35
Hot Stocks
Farnsworth acquires 1.74M Helios and Matheson shares as part of merger pact »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLO

Flowers Foods

$19.10

2.07 (12.16%)

15:32
12/09/16
12/09
15:32
12/09/16
15:32
Upgrade
Flowers Foods rating change  »

Flowers Foods upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$84.28

-0.71 (-0.84%)

, RAD

Rite Aid

$8.20

0.045 (0.55%)

15:25
12/09/16
12/09
15:25
12/09/16
15:25
Periodicals
Walgreens near finalizing Rite Aid divestiture package, CTFN reports »

Walgreens (WBA) is…

WBA

Walgreens Boots Alliance

$84.28

-0.71 (-0.84%)

RAD

Rite Aid

$8.20

0.045 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

BAS

Basic Energy

$0.44

-0.0039 (-0.89%)

15:19
12/09/16
12/09
15:19
12/09/16
15:19
Hot Stocks
Breaking Hot Stocks news story on Basic Energy »

Basic Energy trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
12/09/16
12/09
15:16
12/09/16
15:16
Technical Analysis
NYSE market internals summary »

Breadth is mixed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:16
12/09/16
12/09
15:16
12/09/16
15:16
Technical Analysis
NASDAQ market internals summary »

Volume is heavy for this…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.